Lenalidomide (LEN) is a highly effective immunomodulatory drug (IMiD) for the treatment of patients with newly diagnosed and relapsed multiple myeloma (MM) (Moreau et al, 2015; Nooka et al, 2015) . However, refractoriness to LEN therapy has emerged as a significant clinical problem, prompting studies on the associated mechanisms of resistance. LEN acts directly on the MM cell, modulates the tumour microenvironment and activates the host immune response (Semeraro et al, 2013; Weisel & Kanz, 2014) . In regard to direct effects, LEN has been shown to inhibit MM cell proliferation by upregulating cyclin-dependent kinase (CDK) inhibitors, including p21 (also termed CDKN1A) (Escoubet-Lozach et al, 2009; Hideshima et al, 2000; Verhelle et al, 2007) . LEN also inhibits nuclear factor-jB-induced pro-survival signals and promotes MM cell apoptosis (Chauhan et al, 2010; Mitsiades et al, 2002; Tai et al, 2005) . Anti-MM cell activities of LEN are dependent on the expression of cereblon (CRBN), a component of the E3 ubiquitin ligase complex that also includes DDB1 and CUL4 (Lopez-Girona et al, 2012; Zhu et al, 2011) . Targeting CRBN activity with LEN results in upregulation of p21 and cell cycle arrest (Lopez-Girona et al, 2012; Zhu et al, 2011) . Other studies have demonstrated that sensitivity of MM cells to LEN is suppressed by activation of the WNT/b-catenin pathway . In addition, LEN resistance has been associated with expression of the CD44 surface receptor, a target of WNT/b-catenin-mediated transcription (Bjorklund et al, 2014) , which integrates the tumour microenvironment with properties of cell stemness (Yan et al, 2015) .
Mucin 1 (MUC1) is a heterodimeric glycoprotein that is aberrantly expressed by MM cells and promotes their growth and survival (Baldus et al, 2007; Cloosen et al, 2006; Kawano et al, 2008) . The MUC1 C-terminal transmembrane subunit (MUC1-C) functions as an oncoprotein by interacting with diverse signalling pathways that are associated with transformation (Kufe, 2009a; Li et al, 2003) . In this way, MUC1-C includes a 72 amino acid cytoplasmic domain that is intrinsically disordered and thereby has the capacity to serve as a substrate for multiple kinases and as a binding partner for diverse effectors of gene transcription (Kufe, 2009a; Raina et al, 2015) . For instance, the MUC1-C cytoplasmic domain is phosphorylated by GSK3b and binds directly to b-catenin (Yamamoto et al, 1997) , linking MUC1-C to the WNT pathway. Binding of the MUC1-C cytoplasmic domain to b-catenin is also regulated by receptor tyrosine kinases (RTKs), SRC and protein kinase C (Li et al, 2001a,b; Ren et al, 2002) . The functional significance of the MUC1-C/b-catenin interaction is supported by the demonstration that MUC1-C stabilizes b-catenin by blocking GSK3b-mediated phosphorylation of b-catenin and thereby its proteosomal degradation (Huang et al, 2005) . Moreover, MUC1-C localizes with b-catenin on the promoters of WNT target genes, such as CCND1 and MYC, by forming complexes with TCF4/TCF7L2 and, in turn, promoting gene transcription Rajabi et al, 2012; Tagde et al, 2016a) . The MUC1-C cytoplasmic domain contains a CQC motif that is necessary and sufficient for MUC1-C (i) homodimerization (Leng et al, 2007; Raina et al, 2015 Raina et al, , 2012 , (ii) nuclear localization and (iii) its oncogenic function (Kufe, 2009b; Leng et al, 2007; Raina et al, 2015 Raina et al, , 2012 . Interestingly, expression of MUC1-C with a CQC?AQA mutation in cancer cells is associated with decreases in anchorage-independent growth and tumourigenicity, consistent with a dominant-negative effect for transformation (Kufe, 2009b; Leng et al, 2007) . Based on these findings, we developed cell-penetrating peptides that target the MUC1-C CQC motif and block MUC1-C function (Kufe, 2009b (Kufe, , 2013 Raina et al, 2015 Raina et al, , 2012 . In this way, we found that treatment of MM cells with the MUC1-C inhibitor GO-203 is associated with loss of survival in vitro and in tumour xenograft models (Yin et al, 2010 (Yin et al, , 2012 .
The present studies demonstrate that targeting MUC1-C in combination with LEN is associated with downregulation of the WNT/b-catenin pathway. The results also show that the GO-203/LEN combination is effective in (i) suppressing expression of the WNT target genes, MYC and CD44, and (ii) inducing cell death. Moreover, we report that targeting MUC1-C attenuates LEN resistance in MM cells.
Materials and Methods

Cell culture
Human MM.1S, RPMI8226, H929 and U266 MM cells (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI1640 medium (Cellgro, Manassas, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (GEMINI, West Sacramento, CA, USA), 100 u/ml penicillin, 100 lg/ml streptomycin and 2 mmol/l L-glutamine. Cells were treated with the MUC1-C inhibitor 9 -CQCRRKN), the inactive control peptide CP-2 ([R] 9 -AQARRKN) (AnaSpec, Fremont, CA, USA), LEN (SelleckChem, Houston, TX, USA) or glutathione (GSH) (Sigma-Aldrich, St. Louis, MO, USA). Cells were selected for LEN resistance by exposure to increasing drug concentrations. To establish LEN-resistant cell lines, drug-na€ ıve MM.1S and H929 cells were treated with 1 lmol/l LEN for 5 days, at which time the cells were incubated with fresh 1 lmol/l LEN-supplemented medium for an additional 5 days. Using this approach, exposure to LEN was progressively increased by 1 lmol/l approximately every 10 days until reaching a concentration of 10 lmol/l LEN.
Immunoblot analysis
Cell lysates were prepared as described (Hasegawa et al, 2016; Yin et al, 2010) . Soluble proteins were analysed by immunoblotting with anti-MUC1-C (NeoMarkers, Fremont, CA, USA) anti-b-catenin (Calbiochem, San Diego, CA, USA), anti-MYC (Abcam, Cambridge, MA, USA), anti-TCF4, anti-PKCd, anti-MCL-1 (Santa Cruz, Dallas, TX, USA), antib-actin (Sigma-Aldrich), anti-TIGAR, anti-CD44, anti-poly ADP ribose polymerase (PARP), and anti-BCL-XL (BCL2L1) (Cell Signaling, Danvers, MA, USA). Immune complexes were detected with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescense (GE Healthcare, Piscataway, NJ, USA).
Cell viability and apoptosis assays
Cell viability was assessed by staining with Alamar blue (Invitrogen, Carlsbad, CA, USA). For assessment of cell death, cells were incubated with propidium iodide (PI)/annexin V-fluoresecin isothiocyanate (BD Biosciences, San Jose, CA, USA) for 15 min at room temperature and then analysed by flow cytometry.
Measurement of reactive oxygen species (ROS)levels
Cells were incubated with 5 lmol/l carboxy-2'7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA) (Molecular Probes, Eugene, OR, USA) for 30 min to assess H 2 O 2 -mediated oxidation to 2'7'-dichlorodihydrofluorescein (DCF) as measured at an excitation wavelength of 480 nm and an emission wavelength of 590 nm (Yin et al, 2012) .
Determination of NADPH and GSH levels
Intracellular NADPH concentrations were measured using the Enzychrom NADP/NADPH Assay Kit (BioAssay Systems, Hayward, CA, USA). Intracellular GSH concentrations were assayed using the Bioxytech GSH-400 kit (OXIS International, Burlingame, CA, USA).
Determination of GO-203/LEN combinations
The combined effects of GO-203 and LEN were determined by isobologram analysis using the CalcuSyn software program (Version 2.0) (Biosoft, Cambridge, UK). Using this approach, a combination index (CI) of <1Á0 reflects synergism and a CI > 1Á0 indicates antagonism (Tagde et al, 2016b (Tagde et al, , 2014 .
Purification of primary MM cells
Bone marrow aspirates were obtained from MM patients under approval of the Institutional Review Board of the Dana-Farber Cancer Institute. Mononuclear cells were isolated by density gradient centrifugation through Ficoll-Paque (GE Healthcare) and plasma cells were purified (>95% CD138 + ) by positive selection with anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec, Auburn, CA, USA) (Mimura et al, 2014) .
Analysis of MUC1 and CD44 cell surface expression
For analysis of MUC1 expression, cells were incubated with anti-MUC1-N antibody (Kufe et al, 1984) for 1 h on ice, washed and incubated with phycoerythrin (PE)-conjugated secondary antibody (Invitrogen), washed and then analysed by flow cytometry. For analysis of CD44 expression, cells were incubated with anti-CD44-PE-cyanin 7 (eBioscience, San Diego, CA, USA) for 1 h on ice, washed and then analysed by flow cytometry.
Data analysis
Statistical significance was determined using the Student's t-test (GraphPad Software, La Jolla, CA, USA), where * denotes P < 0Á01; ** denotes P < 0Á05 and # denotes not significant.
Bioinformatics analysis
Microarray data obtained from MM patient samples were downloaded from the Gene Expression Omnibus (GEO, Bethesda, MD, USA) under accession number GSE2658 (n = 559) (Hanamura et al, 2006; Zhan et al, 2007) . Raw signal intensities were RMA normalized across patients. Expression of MUC1 and CD44 was assessed using the Spearman correlation coefficient (Li et al, 2011; Tagde et al, 2016a,b; Takahashi et al, 2015) .
Results
Targeting MUC1-C is effective in combination with LEN
The WNT/b-catenin pathway is of importance to LEN sensitivity of MM cells . In this context, MUC1-C has been shown to stabilize b-catenin (Huang et al, 2005; Yamamoto et al, 1997) , invoking the possibility that targeting MUC1-C could be effective in combination with LEN. Accordingly, we exposed MM cells to the MUC1-C inhibitor GO-203, a cell-penetrating peptide that blocks MUC1-C homodimerization and function (Raina et al, , 2012 (Raina et al, , 2011 Rajabi et al, 2016) (Fig 1A) . Treatment of MM.1S cells with 2Á5 lmol/l GO-203 or 2 lmol/l LEN had no apparent effect on b-catenin levels ( Fig 1B) . Significantly, however, treatment with GO-203 and LEN resulted in downregulation of b-catenin ( Fig 1B) . The WNT/b-catenin pathway has been linked to MYC expression in MM cells (Sukhdeo et al, 2007) . Moreover, we have shown that MUC1-C drives MYC activation in MM cells by a b-catenin-mediated mechanism (Tagde et al, 2016a) . In those studies, treatment of MM cells with 5 lmol/l GO-203 markedly downregulated b-catenin and MYC (Tagde et al, 2016a) . Accordingly, we used a lower concentration of 2Á5 lmol/l GO-203 in the present work to assess the effects of combining GO-203 with LEN. In this way, we found that the GO-203/LEN combination markedly suppresses MYC, and as a control, not the TCF4 transcription factor ( Fig 1B) . As such, we focused our studies of combining GO-203 with LEN on the WNT/b-catenin pathway. Treatment of MM cells with GO-203 results in the disruption of redox balance (Yin et al, 2010 (Yin et al, , 2012 . Addition of exogenous GSH or the GSH precursor N-acetylcysteine (NAC) has been used to re-establish GO-203-induced decreases GSH levels and block ROS-induced MM cell death (Yin et al, 2012 (Yin et al, , 2014 . We therefore added GSH to the GO-203/LEN-treated MM.1S cells and found reversal of b-catenin and MYC downregulation ( Fig 1B) . Similar results were obtained when RPMI8226 cells were treated with GO-203 and LEN; that is (i) more than additive effects in suppressing b-catenin and MYC, and (ii) attenuation of this response with GSH ( Fig 1C) . Based on these findings and the dependence of MM cells on MYC for survival (Delmore et al, 2011; Holien et al, 2012; Mertz et al, 2011) , we examined whether the combination of GO-203 and LEN at different concentrations of these agents induces synergistic anti-MM activity. MM.1S cells were treated with GO-203 at 1Á5, 2 and 2Á5 lmol/l and with LEN at 1 and 2 lmol/l based on the effects of each agent alone (Fig 1D, left) . Isobologram analysis of cell viability demonstrated that the combination of these agents is more than additive, with CI values <1 (Fig 1D, right) . Analysis of RPMI8226 cells treated with GO-203 and LEN confirmed the more than additive anti-MM activity of these agents (Fig 1E) . GO-203 and LEN also induced synergistic killing of U266 MM cells ( Figure S1A ), supporting the notion that these agents are effective when used in combination. Of note, a narrow range of GO-203 concentrations was used in the combination studies based on the steep dose-response curves for this agent. The fraction affected (FA) values are reflective of using this approach and the CI values obtained are consistently more than additive for MM.1S, RPMI8226, U266 and H929 (Figs 1D, E and S1A, S1B) cells.
Combining GO-203 and LEN disrupts redox balance
The observation that GSH reverses the combined effects of GO-203/LEN on suppression of b-catenin and MYC prompted studies of these agents on ROS levels. Notably, the GO-203/LEN combination was associated with greater increases in H 2 O 2 than that obtained with either agent alone in MM.1S (Fig 2A) and RPMI8226 (Fig 2B) cells. Targeting MUC1-C in MM cells increases ROS, partly by decreasing expression of the fructose-2,6-bisphosphatase p53-inducible regulator of glycolysis and apoptosis (TIGAR) and thereby shunting of the glycolytic intermediate glucose-6-phosphate (G6P) into the pentose phosphate pathway (PPP) (Yin et al, 2010 (Yin et al, , 2012 . Interestingly, the GO-203/LEN combination was more effective in downregulating TIGAR than either agent alone (Fig 2C, D) . These results invoked the possibility that the combination could affect shunting into the PPP and, in turn, the production of NADPH and GSH (Patra & Hay, 2014) . Indeed, GO-203/LEN treatment of MM.1S and RPMI8226 cells was associated with suppression of NADPH ( Fig 2E) and GSH (Fig 2F) levels that were greater than that found with either agent alone. Moreover, these MM cells responded to the GO-203/LEN combination with decreases in TIGAR (Fig 2C, D) , NADPH ( Fig 2E) and GSH ( Fig 2F) that were reversed in part with GSH. Similar results were obtained with U266 cells (Figs S2A-S2D ), indicating that the interaction between GO-203 and LEN is mediated by a ROSmediated mechanism.
GO-203/LEN combination induces ROS-mediated cell death
In concert with the effects of GO-203/LEN on disruption of redox balance, we found that the GO-203/LEN combination is effective in inducing cleavage of the caspase-3 substrates, PARP and PKCd, and that these responses are attenuated by GSH (Fig 3A, B) . To extend this analysis, we assessed the effects of GO-203 and LEN on cell death as determined by PI/annexin V staining. Using this approach, the percentage of apoptotic/necrotic MM.1S cells was increased by the combination (79%) as compared to that obtained with or LEN (37%) alone (Fig 3C) . Treatment of RPMI8226 cells with the GO-203/LEN combination was also associated with increased apoptotic/necrotic death ( Fig 3D) . Additionally, GO-203/LEN-induced death of both MM.1S Lysates were immunoblotted (IB)with the indicated antibodies. E and F. The indicated cells were analysed for relative NADPH (E) and glutathione (GSH) (F) levels (mean AE SD of 3 determinations) as compared with that obtained with control cells (assigned a value of 1). These results are representative of 3 independent experiments. *P < 0Á01.
and RPMI8226 (Fig 3E) cells was attenuated by GSH, consistent with a ROS-mediated mechanism.
Effects of targeting MUC1-C in LEN-resistant (LR) cells
To assess the effects of targeting MUC1-C in a setting of LEN resistance, we grew MM.1S cells in the presence of increasing concentrations of LEN. In this way, we generated MM.1S/LR cells selected for survival in 10 lmol/l LEN (Fig 4A) . Notably, LEN resistance was associated with upregulation of MUC1-C, b-catenin and MYC (Fig 4B) . Selection of H929 cells for LEN resistance (Fig 4C) was also associated with selective increases in MUC1-C, b-catenin and MYC expression (Fig 4D) . In contrast to the consistent activation of the MUC1-C?b-catenin?MYC pathway, LEN resistance had varying effects on levels of the BCL2 family proteins, BCL-XL and MCL1 ( Figs S3A, B) . In addition and in comparison to the drug na€ ıve cells, LEN-induced increases in ROS were abrogated in LEN resistant cells (Figs S3C, D) . As found for drug-na€ ıve MM.1S cells, treatment of MM.1S/LR cells with GO-203 resulted in suppression of b-catenin and MYC ( Fig 4E) . By contrast, treatment with the control inactive CP-2 peptide ( Fig 1A) had no apparent effect (Fig 4E) . Similar results were obtained with H929/LR cells (Fig 4F) , indicating that LEN resistance is associated with increases in WNT/b-catenin signalling, which are sensitive to targeting MUC1-C with GO-203.
Targeting MUC1-C attenuates LEN resistance
MM cells are dependent on MYC for survival (Delmore et al, 2011; Holien et al, 2012; Mertz et al, 2011; Tagde et al, 2016a) . In this context, the demonstration that targeting MUC1-C downregulates MYC in LEN-resistant cells invoked the potential for sensitivity to GO-203-induced killing. Indeed, MM.1S/LR cells were sensitive to treatment with GO-203, as determined by induction of apoptosis/necrosis ( Fig 5A) . As a control, treatment with the inactive peptide CP-2 ( Fig 1A) had little, if any, effect (Fig 5A) . H929/LR cells were also sensitive to GO-203-, but not CP-2, induced apoptosis/necrosis (Fig 5B) , further supporting a lack of cross-resistance between GO-203 and LEN. To extend this Isobologram analysis of MM.1S/LR cell viability at different concentrations of these agents demonstrated that the combination of GO-203 and LEN is more than additive, with a CI value <1 (Fig 5C) . Similar results were obtained when H929/ LR cells were treated with the GO-203/LEN combination (Fig 5D) , indicating that GO-203 reverses LEN resistance.
Effects of targeting MUC1-C on CD44 expression
Resistance of MM cells to LEN has been linked to involvement of WNT/b-catenin and CD44 (Bjorklund et al, 2014 . In this context, analysis of MM.1S (Fig 6A) and H929 ( Fig 6B) cells for CD44 expression demonstrated significant increases in association with LEN resistance. CD44 expression is regulated by diverse signals, including the WNT/ b-catenin pathway (Smith et al, 2014; Wong & Pignatelli, 2002; Yan et al, 2015) . Accordingly, we questioned if targeting MUC1-C affects CD44 levels in MM cells. Indeed, treatment of MM.1S/LR cells with GO-203, but not CP-2, was associated with marked suppression of CD44 (Fig 6C) . H929/LR cells also responded to GO-203 with downregulation of CD44 expression (Fig 6D) . To determine whether the results obtained with MM cell lines extend to primary MM cells, bone marrow samples from patients with active LENresistant MM were separated into CD138 + populations.
Treatment of MUC1-positive CD138 + cells from LEN-sensitive Patient 1 with GO-203 was associated with suppression of CD44 expression as determined by flow cytometry (Fig 6E, left; Fig S4) . Similar results were obtained with MUC1-expressing MM cells obtained from LEN-resistant Patient 2 (Fig 6E, middle; Fig S4) and LEN-resistant Patient 3 (Fig 6E, right; Fig S4) , confirming that targeting MUC1-C is associated with downregulation of CD44 expression. To further investigate the relationship between MUC1 and CD44 in MM, we analysed the Gene Expression Omnibus (GEO) dataset GSE2658 obtained from primary MM cells (n = 559). Notably, we found that MUC1 levels significantly correlated with CD44 expression (Fig 6F) , further supporting the notion that, as found for MYC (Tagde et al, 2016a) , MUC1-C also contributes to CD44 expression. 
Discussion
LEN is an effective agent in the treatment of MM; however, most patients invariably develop resistance to this agent (Moreau et al, 2015; Nooka et al, 2015) . LEN resistance has been linked, at least in part, to activation of the WNT/ b-catenin pathway (Bjorklund et al, 2014 . The findings that MUC1-C is aberrantly expressed in MM cells (Baldus et al, 2007; Cloosen et al, 2006; Kawano et al, 2008) and promotes activation of WNT/b-catenin signalling (Fig 7A ) (Huang et al, 2005; Yamamoto et al, 1997) therefore provided support for the notion that MUC1-C contributes to LEN resistance. Indeed, the present results demonstrate that, whereas LEN alone has little, if any effect, on b-catenin, treatment of MM cells with low concentrations of GO-203 in combination with LEN is associated with suppression of b-catenin levels. The GO-203/LEN combination was also effective in downregulating expression of the WNT target gene, MYC. Notably, these effects of the GO-203/LEN combination on b-catenin and MYC were reversed by the antioxidant GSH, providing evidence for a ROS-mediated mechanism (Fig 7B) . In this context, ROS negatively modulates the WNT pathway by downregulation of b-catenin (Finkel, 2011; Shin et al, 2004) . Targeting MUC1-C in MM cells has been linked to increases in ROS and, in turn, ROSmediated decreases in TIGAR, NADPH and GSH (Yin et al, 2010 (Yin et al, , 2012 . Interestingly, the GO-203/LEN combination resulted in significant increases in ROS compared to that with either agent alone. In concert with these results, GO-203/LEN was highly effective in downregulating TIGAR by a ROS-mediated mechanism and in suppressing NADPH and GSH levels. Moreover, the GO-203/LEN combination was The results are expressed as relative CD44 levels (mean AE SD of 3 determinations) as compared to that obtained for CTL cells (assigned a value of 1). F. Microarray gene expression data from GEO dataset GSE2658 (n = 559) was RMA normalized and the correlation between MUC1 and CD44 expression in MM patients was assessed by Spearman correlation, where P < 0Á05 was considered as statistically significant. *P < 0Á01; **P < 0Á05. synergistic in killing MM cells by ROS-induced apoptosis/ necrosis. These findings thus provided support for a model in which targeting MUC1-C in combination with LEN disrupts redox balance and thereby suppresses the WNT/b-catenin pathway and survival (Fig 7B) .
Previous work demonstrated that targeting MUC1-C is synergistic with bortezomib (BTZ) in inducing ROSmediated MM cell death (Yin et al, 2012) . Moreover, GO-203 re-sensitized BTZ-resistant MM cells to BTZ treatment, as evidenced by the combination synergistically increasing ROS levels and cell death (Yin et al, 2012) . The finding that targeting MUC1-C in MM cells is effective in combination with LEN thus prompted further studies to determine whether GO-203 has activity in the setting of LEN resistance. For this purpose, we generated LEN-resistant MM cells and found them somewhat more sensitive to GO-203 as compared to LEN-na€ ıve MM cells. In addition, when LEN-resistant cells were treated with the GO-203/LEN combination, there was greater killing than that obtained with GO-203 or LEN alone. These findings supported the premise that GO-203 attenuates resistance to LEN. In further support, treatment of LEN-resistant MM cells with the GO-203/LEN combination also resulted in marked increases in ROS that were not observed with either agent alone. Treatment of LENresistant MM cells with GO-203/LEN was also associated with more than additive decreases in NADPH and GSH, consistent with the disruption of redox balance observed in drug-na€ ıve MM cells. Additionally, LEN-resistant MM cells responded to the GO-203/LEN combination with more than additive loss of survival. Addiction to MYC has been reported for MM cells based on induction of death in response to a MYC inhibitor (Holien et al, 2012) . In addition, targeting MYC transcription with the BET bromodomain inhibitor JQ1 inhibits MM cell survival and tumour growth (Delmore et al, 2011; Mertz et al, 2011) . Thus, the effects of treating LEN-resistant MM cells with GO-203 could be a result of MYC downregulation. However, based on the finding that GSH reverses the effects of the GO-203/LEN combination on LEN-resistant cells, our results support a model in which these agents act more than additively by disruption of redox balance and thereby downregulation of WNT/b-catenin signalling (Fig 7B) . Thus, as found for BTZresistant MM cells (Yin et al, 2012) , targeting MUC1-C with GO-203 could be effective in certain settings of LEN-resistance.
Increasing evidence has supported the importance of the WNT/b-catenin pathway and MYC in promoting MM cell growth and survival (Derksen et al, 2004; Tagde et al, 2016a) . As a result, the development of agents that target the b-catenin/TCF complex in MM cells has been a focus of investigation (Sukhdeo et al, 2007) . Targeting MUC1-C with GO-203 abrogates the interaction of MUC1-C with b-catenin and TCF4, and the occupancy of these complexes on the promoters of WNT target genes . In this context, MUC1-C drives MYC expression by b-cateninmediated activation of the MYC promoter in MM cells (Tagde et al, 2016a) . Thus, targeting MUC1-C with silencing or pharmacologically with GO-203 results in the downregulation of b-catenin and MYC (Tagde et al, 2016a) . To extend the role of MUC1-C in conferring LEN resistance, we also investigated the effects of targeting MUC1-C on activation of the WNT/b-catenin target gene, CD44 (Wielenga et al, 1999) . In this regard, CD44 is overexpressed in LEN-resistant MM cell lines and primary cells (Bjorklund et al, 2014) . Moreover, silencing CD44 attenuates MM cell adhesion and LEN resistance (Bjorklund et al, 2014) . In concert with the effects of targeting MUC1-C on suppression of WNT/b-catenin signalling, we found that GO-203 treatment of LENna€ ıve and -resistant MM cell lines is associated with downregulation of CD44 levels (Fig 7B) . Similar results were obtained with primary CD138 + MM cells. Moreover, analysis of microarray data obtained from primary MM cells provided further support for a significant relationship between MUC1 and CD44, indicating that targeting MUC1-C could contribute to the treatment of LEN-sensitive and -resistant MM by suppressing CD44 expression (Fig 7B) . Based on these findings, we are currently analysing a larger cohort of primary MM samples from patients who are resistant to LEN Other studies demonstrating that histone deacetylase inhibitors (HDACi) are synergistic with LEN in inducing MM cell killing (Hideshima et al, 2015) lend support for further investigations that combine GO-203 with an HDACi and LEN for the treatment of LEN-resistant disease. With regard to translational relevance, a Phase I trial of GO-203 has been completed in patients with advanced solid tumours. Moreover, based on the marked synergy between GO-203 and decitabine in AML (Tagde et al, 2016b) , a Phase IIb trial of this combination is underway for patients with relapsed/refractory acute myeloid leukaemia. Therefore, the present findings could provide the experimental basis for treatment of LENresistant MM with GO-203 alone or in combination with other targeted agents.
